Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story

With an estimated 46 million Americans leaving the pharmacy counter each month without filling a prescription because of cost—a gap that GoodRx Research has documented persisting across insured and uninsured populations alike¹—CMS Administrator Mehmet Oz, MD, used a June 2 White House press briefing to lay out a series of policy advances the Trump administration says are reshaping the economics of American health care, from a drug pricing transparency tool now reaching millions to a landmark expansion of glucagon-like peptide-1 (GLP-1) coverage for people with Medicare.²

Oz, who was confirmed as CMS Administrator by a 53-45 party-line Senate vote in April 2025, had navigated persistent Democratic scrutiny since his nomination—including concerns raised by Senator Elizabeth Warren (D, Massachusetts) and colleagues about his past advocacy for Medicare Advantage over traditional Medicare and financial ties to UnitedHealth Group, the country's largest Medicare Advantage insurer, which had drawn allegations of potential conflict of interest given its stake in his proposed Medicare policies.^3,4

TrumpRx Adds 160 Drugs—Expert Assessments of Real-World Savings Remain Mixed

TrumpRx.gov—launched February 5, 2026, as a free, cash-based price transparency and referral platform—received its latest expansion on the day of the briefing, with Oz announcing 160 additional listings that brought the site's total to approximately 750 drugs, covering roughly 4 out of 5 prescriptions dispensed at US pharmacies.

"You would never buy a car without knowing the cost of the car—some of these medications cost what a car costs," Oz said, underscoring the administration's transparency rationale. Since a launch event 2 weeks prior, he reported that the site attracted 12 million unique visitors and generated an estimated $500 million in consumer savings.

The June 2 announcement followed a significant expansion in May, when the administration partnered with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to add more than 600 generic medications to the platform—shifting TrumpRx from a largely brand-name formulary toward the roughly 90% of US prescriptions filled with generics.^2,5 Cost Plus Drugs, which applies a fixed 15% markup and offers direct-to-patient mail-order distribution for more than 2300 medications, was integrated alongside interactive neighborhood price maps, allowing consumers to compare local pharmacy pricing. The website functions as an aggregator and coupon hub rather than a direct dispensary, routing consumers to manufacturer direct-to-consumer sites or partner pharmacies.⁵

The platform's underlying policy framework is the administration's most-favored-nation (MFN) drug pricing strategy, under which all 17 of the largest branded pharmaceutical companies—accounting for more than 80% of the branded market—agreed to price medications in the US at parity with prices in other countries. The Council of Economic Advisors estimated that the initiative would produce approximately $600 billion in savings over the next decade. Oz expressed support for congressional codification of the MFN framework to ensure durability across future administrations.²

Independent assessments have been more measured. Previous coverage from The American Journal of Managed Care^® (AJMC^®) has noted that TrumpRx does not always offer the most competitive prices for cash-paying consumers and that purchases made through the platform do not count toward patients' insurance deductibles, limiting the site's practical value for many insured individuals.^6,7 The website is most useful for those who are uninsured or whose plans do not cover specific medications. Robert Andrews, former US Representative and CEO of the Health Transformation Alliance, observed in an interview with AJMC that while TrumpRx could meaningfully improve access to lower-cost generics, its overall affordability impact may remain constrained—particularly for the high-cost specialty therapies that generate the largest out-of-pocket burdens for patients.⁸

How the administration communicates savings figures has also drawn scrutiny. At a Senate hearing in April, HHS Secretary Robert F. Kennedy Jr acknowledged that President Donald Trump employs a nonconventional method of calculating percentage price reductions—characterizing, for example, a drop from $600 to $10 as a "600% reduction."⁹ Senator Warren challenged that framing, noting that under standard arithmetic the same price drop would represent approximately a 98% reduction, and pressed administration officials to be more precise in communicating actual savings to patients.

Medicare GLP-1 Coverage Expanded: Eligible Beneficiaries to Pay $50 Per Month Starting July 1

In a significant policy announcement for people living with obesity and related metabolic conditions, Oz confirmed that Medicare beneficiaries who qualify for GLP-1 receptor agonists will be able to obtain those therapies for $50 per month beginning July 1, 2026.² List prices for branded agents in this class currently exceed $1000 per month.

Oz cited the downstream clinical implications of obesity as central to the coverage rationale, noting that effective weight management can mitigate risk for type 2 diabetes, hypertension, kidney failure, cardiovascular disease, stroke, dementia, and certain cancers. He expressed optimism that, when used appropriately and consistently, these medications could ultimately yield net savings for the Medicare program by reducing costly downstream complications.

Fraud, Waste, and Abuse Enforcement: Hospice Suspensions, State Audits, and a $2 Billion California Recovery

Oz devoted substantial time to the administration's anti-fraud efforts under the vice president's White House Anti-Fraud Task Force, describing a coordinated, multiagency response involving CMS, the Office of Inspector General, the Federal Bureau of Investigation, and the Department of Justice.

He characterized “fraud” in these programs as “organized” and “sophisticated,” noting that “bad actors” require only a Medicare beneficiary identification number to begin billing against federal funds. He described the administration's recently announced Minnesota autism services fraud takedown, involving tens of millions of dollars in alleged theft. Oz highlighted that the state had been forced to eliminate a publicly funded benefit program after its costs escalated from approximately $1 million to over $100 million annually due to fraud.

In California, Oz noted that the administration had suspended payments to approximately 850 hospice providers—nearly half of all such providers in the state—after determining that having one-third of the nation's hospice programs concentrated in Los Angeles alone was “not clinically plausible.” He said “fraudulent operators” had subsequently migrated to home health and personal care services sectors in neighboring states. The administration also notified California that the state owed the federal government $2 billion for coverage of individuals in the country illegally, with approximately half already recovered.

“We've been aggressively going after states: red and blue. We wrote a letter to Florida. The difference [from California] was Florida responded by saying, ‘We know we have a problem. We're going to double down. We want a moratorium on all of our durable medical equipment suppliers.’ And why? Because there are twice as many durable medical equipment suppliers in South Florida than McDonald's. Again, not really possible, unless you're looking the other way. We're not looking the other way. We're aggressively taking on these challenges… If you're defrauding our most vulnerable citizens in America, do not walk away from this threat. Run away from us, because we're coming after you,” Oz warned.

Oz also addressed the administration's newly finalized Medicaid work requirement rule, describing it as requiring able-bodied adult beneficiaries to work, pursue education, or volunteer for at least 20 hours per week to maintain eligibility, a framework modeled on the Temporary Assistance for Needy Families structure established during the Clinton administration in the 1990s.

On the President's Fourth Physical and Questions of Cognitive Health

When reporters pressed Oz about why Trump had undergone 4 medical examinations in a single year of his second term, Oz offered a characteristically candid response.

"I think he likes the results," Oz told reporters. He added that the frequency of checkups reflected the president's characteristically "meticulous" disposition, noting that the same impulse that drives late-night phone calls also drives him to "want to know all the numbers and keep on top of them."

Oz described the president's most recent laboratory values—including cholesterol and blood pressure—as within "excellent parameters” and cited the president's publicly observable energy and cognitive output as clinical evidence of good health. "That amount of energy and that amount of mental acuity does not exist in a vacuum," he said. "You have to have a vessel to carry it."

COVID-19 Vaccine Policy, ACA Enrollment Integrity, and Pharmaceutical Reshoring

On COVID-era vaccine mandates, Oz indicated the administration supported a state-driven framework for vaccine policy decisions, aligned with a recent executive order. He expressed that ideology and fear—rather than what he called "gold standard science"—had undermined public trust in health policy during the pandemic, and that restoring that trust required transparent, evidence-based guidance for families and state governments.

Regarding the Affordable Care Act (ACA), Oz raised concerns about enrollment integrity, estimating that approximately 35% of current exchange enrollees—potentially 5 to 6 million people—may not have legitimate enrollments, citing cases of duplicate multistate coverage or simultaneous Medicaid enrollment. The administration had recently issued a rule initiating a process to identify and remove ineligible enrollees.

The ACA marketplace in 2026 presents a picture that partially validates Oz's enrollment integrity concerns while also revealing affordability pressures that extend well beyond the administration's fraud narrative. A July 2025 CMS analysis of 2024 enrollment data confirmed that an average of 1.6 million Americans per month were simultaneously enrolled in both Medicaid or Children's Health Insurance Program (CHIP) and a subsidized ACA Exchange plan, with an additional 1.2 million enrolled in Medicaid across multiple states—2.8 million people in potentially improper concurrent enrollments that CMS estimated were costing taxpayers approximately $14 billion annually.¹⁰

A November 2025 Center for Medicaid and CHIP Services Informational Bulletin issued to state Medicaid directors provided the regulatory context for the cleanup: while interstate data matching through the Public Assistance Reporting Information System has been federally required since 2009, pandemic-era statutory restrictions had halted the Medicaid Periodic Data Matching process for several years, allowing concurrent enrollment to accumulate significantly before eligibility checks were reinstated.¹¹

CMS published a parallel program integrity document summarizing the technical mechanisms—including state partnerships and exchange-based data matching—by which duplicate enrollments would be identified and resolved.¹² Clinical and policy reporting at the time highlighted the complexity of unwinding these overlapping enrollments without inadvertently displacing people who had been enrolled in multiple programs, sometimes without their own knowledge.¹³

At the same time, AJMC reporting published 2 weeks before the briefing documented that the expiration of enhanced premium tax credits at year-end 2025 had triggered the steepest single-year marketplace contraction on record—average deductibles surging 37% to a record $3786 and effectuated enrollment projected to fall 21.5% to approximately 17.5 million—driven substantially by affordability pressures rather than enforcement alone.¹⁴

A Wakely Consulting Group analysis found that 14% of January 2026 ACA enrollees did not make their first premium payment—roughly double the normal rate—with those who remained enrolled approximately 10% less healthy by expected cost, a pattern of adverse selection with implications for future premiums across the market.¹⁵ Together, these data suggest that while the enrollment integrity problems Oz described are federally documented and real, the marketplace's current disruption reflects both the necessary cleanup of duplicate enrollments and a broader affordability crisis that subsidy policy, not eligibility verification alone, will need to address.

On pharmaceutical manufacturing, Oz described ongoing domestic investment by companies in the MFN framework, citing recently opened and under-construction US facilities as evidence that reshoring was already underway.¹

References

1. Marsh T, Guttentag S. Nearly a third of Americans aren't filling their prescriptions because of high costs. GoodRx. Updated July 2, 2025. Accessed June 3, 2026. https://www.goodrx.com/healthcare-access/research/third-of-americans-dont-fill-prescriptions-due-to-cost
2. WATCH: Dr. Oz announces additions to TrumpRx, comments on Pulte role and Trump health. PBS NewsHour. Published June 2, 2026. Accessed June 3, 2026. https://www.pbs.org/newshour/politics/watch-live-white-house-briefing-with-dr-oz-may-address-pultes-new-role-iran-war
3. Joszt L. Dr Oz confirmed by the Senate along party lines to lead CMS. AJMC. April 3, 2025. Accessed June 3, 2026. https://www.ajmc.com/view/dr-oz-confirmed-by-the-senate-along-party-lines-to-lead-cms
4. Grossi G. Dr Oz's Medicare proposals face scrutiny from Democrats. AJMC. December 11, 2024. Accessed June 3, 2026. https://www.ajmc.com/view/dr-oz-s-medicare-proposals-face-scrutiny-from-democrats
5. Steinzor P. TrumpRx expands generic drug offerings with Mark Cuban partnership, Amazon Pharmacy support. AJMC. May 19, 2026. Accessed June 3, 2026. https://www.ajmc.com/view/trumprx-expands-generic-drug-offerings-with-mark-cuban-partnership-amazon-pharmacy-support
6. Shaw M. TrumpRx launch brings savings — and uncertainty. AJMC. February 5, 2026. Accessed June 3, 2026. https://www.ajmc.com/view/trumprx-launch-brings-savings-and-uncertainty
7. Bonavitacola J. FAQs surrounding TrumpRx as rollout of the service continues. AJMC. March 13, 2026. Accessed June 3, 2026. https://www.ajmc.com/view/faqs-surrounding-trumprx-as-rollout-of-the-service-continues
8. Bonavitacola J. Two months later, success of TrumpRx is mixed: are lower prices really available? AJMC. March 27, 2026. Accessed June 3, 2026. https://www.ajmc.com/view/two-months-later-success-of-trumprx-is-mixed-are-lower-prices-really-available-
9. Whisnant G. RFK Jr. says Trump has 'different way' of calculating percentages. Newsweek. April 22, 2026. Accessed June 3, 2026. https://www.newsweek.com/rfk-jr-trump-different-way-calculating-drug-prices-warren-senate-11864840
10. CMS. CMS finds 2.8 million Americans potentially enrolled in two or more Medicaid/ACA Exchange plans. Press release. July 17, 2025. Accessed June 4, 2026. https://www.cms.gov/newsroom/press-releases/cms-finds-2-8-million-americans-potentially-enrolled-two-or-more-medicaid-aca-exchange-plans
11. Brillman D. Ensuring Medicaid eligibility integrity by addressing concurrent Medicaid and Children's Health Insurance Program (CHIP) enrollment across states. CMCS Informational Bulletin. Centers for Medicare & Medicaid Services. November 6, 2025. Accessed June 4, 2026. https://www.medicaid.gov/federal-policy-guidance/downloads/cib11062025.pdf
12. Dual enrollment fast facts. CMS Program Integrity. 2025. Accessed June 4, 2026. https://www.cms.gov/files/document/cpi-dual-enrollment-fast-facts.pdf
13. Frieden J. Removing duplicate enrollees from Medicaid, ACA plans is not as easy as you’d think. MedPage Today. August 15, 2025. Accessed June 4, 2026. https://www.medpagetoday.com/publichealthpolicy/medicaid/117029
14. Grossi G. ACA Marketplace deductibles surge $1000 in 2026 as enhanced tax credits expire. AJMC. May 20, 2026. Accessed June 4, 2026. https://www.ajmc.com/view/aca-marketplace-enrollment-and-affordability-take-historic-hit-as-enhanced-tax-credits-expire
15. Bonavitacola J. Percentage of enrollees who fail to make ACA payments rises to 14%. AJMC. April 15, 2026. Accessed June 4, 2026. https://www.ajmc.com/view/percentage-of-enrollees-who-fail-to-make-aca-payments-rises-to-14-